Lycia Therapeutics, Inc. Form S-1 — Oct 5, 2026
Lycia Therapeutics filed an S-1 for its initial public offering on Nasdaq under symbol LYCA, with Jefferies, TD Cowen, Evercore ISI and Guggenheim as joint bookrunners. Share count and price range are not yet disclosed. The clinical-stage biotech is developing LYTAC extracellular protein degraders, with Phase 1 trials of LCA-0061 (IgE, food allergy) and LCA-0321 (Graves' disease) underway. Preliminary Phase 1 data showed a mean maximum IgE reduction of 96% after a single 70 mg subcutaneous dose, with no safety signals observed.
Key figures
- Revenue
- 6741000
- Total Debt
- 11845000
- Total Assets
- 156760000
- Cash Position
- 148091000
- Accumulated deficit
- 136756000
- R and d expense 2025
- 40507000
- Net loss six months 2026
- 19200000
- Collaboration revenue 2024
- 14936000
- Capital raised since inception
- 266600000
- Lca 0061 mean max Ig E reduction
- 96%
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.